4XS.HM - EXPRESS SCRIPTS HLDG

Hamburg - Hamburg Delayed Price. Currency in EUR
81.13
-0.93 (-1.13%)
At close: 8:01AM CEST
Stock chart is not supported by your current browser
Previous Close82.06
Open81.13
Bid0.00 x 0
Ask0.00 x 0
Day's Range81.13 - 81.13
52 Week Range48.03 - 83.38
Volume11
Avg. Volume0
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • TheStreet.com5 days ago

    Express Scripts' Stock Has a Prescription for Further Gains

    Prices are above the rising 50-day moving average line and the bullish 200-day moving average line. Successful tests of the 200-day line can be seen in April, May and the beginning of August. The daily On-Balance-Volume (OBV) line shows a positive bias with a new rise from early August.

  • Express Scripts' Accredo & Akcea Tie Up to Distribute TEGSEDI
    Zacks7 days ago

    Express Scripts' Accredo & Akcea Tie Up to Distribute TEGSEDI

    Express Scripts (ESRX) likely to gain market traction through distribution of TEGSEDI.

  • See what the IHS Markit Score report has to say about Express Scripts Holding Co.
    Markit7 days ago

    See what the IHS Markit Score report has to say about Express Scripts Holding Co.

    Express Scripts Holding Co NASDAQ/NGS:ESRX

  • Cigna Gets Merger Nod, Forms Management for Unified Entity
    Zacks13 days ago

    Cigna Gets Merger Nod, Forms Management for Unified Entity

    Cigna (CI) forms management as it prepares for new merged entity.

  • 6 Predictable Stocks With Wide Margins of Safety
    GuruFocus.com14 days ago

    6 Predictable Stocks With Wide Margins of Safety

    According to the GuruFocus All-in-One Screener , the following stocks have high business predictability ratings and a wide margin of safety. Warning! GuruFocus has detected 4 Warning Signs with CAI. The company has a three-star business predictability rating and, according to the discounted cash flow calculator, has a 53% margin of safety at $22.87 per share.

  • Moody's24 days ago

    Halfmoon Parent, Inc. -- Moody's assigns a P-2 commercial paper rating to Halfmoon Parent, Inc.

    Rating Action: Moody's assigns a P-2 commercial paper rating to Halfmoon Parent, Inc. New York, September 21, 2018 -- Moody's Investors Service (Moody's) has assigned a Prime-2 short term rating, on review for downgrade, to the commercial paper (CP) program of Halfmoon Parent, Inc. (Halfmoon), a wholly owned subsidiary of Cigna Corporation (Cigna, Baa1 on review for downgrade). This is consistent with Moody's rating of Cigna's short-term commercial paper.

  • Cigna Moves Closer to Express Scripts Buyout With DoJ Nod
    Zacks27 days ago

    Cigna Moves Closer to Express Scripts Buyout With DoJ Nod

    Cigna (CI) clears a significant regulatory hurdle with regards to its proposed acquisition of Express Scripts.

  • See what the IHS Markit Score report has to say about Express Scripts Holding Co.
    Markit27 days ago

    See what the IHS Markit Score report has to say about Express Scripts Holding Co.

    Express Scripts Holding Co NASDAQ/NGS:ESRX

  • Reuters28 days ago

    PRESS DIGEST -Wall Street Journal - Sept 18

    The following are the top stories in the Wall Street Journal. - Apple Inc dodged stinging duties on its smartwatches and wireless earbuds after the U.S. excluded those gadgets from tariffs on $200 billion in Chinese goods, though the tech giant still faces retaliatory measures being weighed by China that could strike iPhone production there. - SpaceX's first paying passenger will be Japanese billionaire Yusaku Maezawa, who is to blast off from earth in 2023, circle the moon and return, the company's founder and chief executive, Elon Musk, said at an event Monday evening.

  • Cigna deal gets antitrust nod, positive sign for CVS/Aetna
    Reuters28 days ago

    Cigna deal gets antitrust nod, positive sign for CVS/Aetna

    The decision bodes well for the pending U.S. antitrust review of CVS Health Corp's (CVS.N) proposed $69 billion acquisition of health insurer Aetna Inc (AET.N). The new company will marry Cigna's business of managing health plans for corporations and the government with Express Scripts' (ESRX.O) role handling pharmacy benefits for those same customers.

  • Cigna deal gets antitrust nod, positive sign for CVS/Aetna
    Reuters28 days ago

    Cigna deal gets antitrust nod, positive sign for CVS/Aetna

    The decision bodes well for the pending U.S. antitrust review of CVS Health Corp's (CVS.N) proposed $69 billion acquisition of health insurer Aetna Inc (AET.N). The new company will marry Cigna's business of managing health plans for corporations and the government with Express Scripts' (ESRX.O) role handling pharmacy benefits for those same customers.

  • Cigna deal gets antitrust nod, positive sign for CVS-Aetna
    Reuters28 days ago

    Cigna deal gets antitrust nod, positive sign for CVS-Aetna

    The decision bodes well for the pending U.S. antitrust review of CVS Health Corp's (CVS.N) proposed $69 billion acquisition of health insurer Aetna Inc (AET.N). The new company will marry Cigna's business of managing health plans for corporations and the government with Express Scripts' (ESRX.O) role handling pharmacy benefits for those same customers.

  • Congratulations, Cigna! Now Comes the Hard Part.
    Bloomberg28 days ago

    Congratulations, Cigna! Now Comes the Hard Part.

    Cigna Corp. has successfully dodged two giant obstacles in its attempt to purchase pharmacy-benefit manager Express Scripts Holding Co. First, it got past Carl Icahn, who tried to convince investors to vote no on the deal in August, only to drop the effort days later after giving it further thought.

  • Cigna-Express Scripts Deal Is Cleared by U.S. Justice Department
    Bloomberg28 days ago

    Cigna-Express Scripts Deal Is Cleared by U.S. Justice Department

    Antitrust enforcers signed off on Cigna Corp.’s $54 billion takeover of pharmacy-benefit manager Express Scripts Holding Co., clearing one of two health-care deals that stand to reshape the industry. Approval by the Justice Department smooths the way for the deal to wrap up by the end of the year, the companies said Monday in a joint statement. Express Scripts shares rose 3.7 percent to $95.23 at the close in New York.

  • Why Express Scripts Gained 11% in August
    Motley Foollast month

    Why Express Scripts Gained 11% in August

    Second-quarter results were strong enough to lift the company's sales outlook last month.

  • 5 Stocks With Low Price-Sales Ratios
    GuruFocus.comlast month

    5 Stocks With Low Price-Sales Ratios

    According to the GuruFocus All-in-One Screener, the following stocks with market caps over $5 billion look cheap since they are trading with low price-sales ratios. Warning! GuruFocus has detected 7 Warning Signs with BTI. British American Tobacco PLC (BTI) is trading around $49 per share with a price-sales ratio of 3.86 and a price-earnings ratio of 2.10.

  • The Wall Street Journal2 months ago

    [$$] Shareholders Approve Cigna-Express Scripts Deal

    Cigna Corp. and Express Scripts Holding Co. shareholders overwhelmingly supported Cigna’s $54 billion purchase of the pharmacy-benefit manager, a deal that activist investor Carl Icahn initially sought to block. The deal received the backing of about 90% of Cigna shareholders, the health insurer said Friday, citing a preliminary vote tally. Of the Express Scripts shareholders who voted Friday, 99% approved the deal.

  • PR Newswire2 months ago

    Express Scripts Stockholders Approve Acquisition by Cigna

    ST. LOUIS, Aug. 24, 2018 /PRNewswire/ -- Stockholders of Express Scripts Holding Company (ESRX) today approved the proposed acquisition of Express Scripts by Cigna. Based on a preliminary tabulation, approximately 78 percent of the shares of Express Scripts common stock outstanding and entitled to vote adopted the Agreement and Plan of Merger with Cigna and certain of its subsidiaries.

  • Reuters2 months ago

    Cigna shareholders approve $52 bln Express Scripts acquisition

    Cigna Corp shareholders on Friday voted in favor of the health insurer's proposed $52 billion acquisition of pharmacy benefit manager Express Scripts Holding Co, but the deal still needs antitrust approval to move forward. The vote for the merger was expected after billionaire activist investor Carl Icahn walked away last week from his eleventh-hour attempt to rally shareholders to reject the deal. The U.S. Department of Justice is still conducting an antitrust review of the combination that is not expected to close until later this year.

  • Should You Care About Express Scripts Holding Company’s (NASDAQ:ESRX) Cash Levels?
    Simply Wall St.2 months ago

    Should You Care About Express Scripts Holding Company’s (NASDAQ:ESRX) Cash Levels?

    Two important questions to ask before you buy Express Scripts Holding Company (NASDAQ:ESRX) is, how it makes money and how it spends its cash. What is left after investment, determinesRead More...

  • Express Scripts staking out million dollar gene therapies
    Reuters2 months ago

    Express Scripts staking out million dollar gene therapies

    Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs. Express Scripts is in talks with biotechnology companies Biomarin Pharmaceutical Inc (BMRN.O), Spark Therapeutics Inc (ONCE.O) and Bluebird Bio Inc (BLUE.O) to have its specialty pharmaceutical business exclusively distribute their new gene therapies when they are expected to become available in 2019 and 2020, Chief Medical Officer Steve Miller told Reuters in an interview.

  • Reuters2 months ago

    Focus: Express Scripts staking out million-dollar gene therapies

    Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs. Express Scripts is in talks with biotechnology companies Biomarin Pharmaceutical Inc, Spark Therapeutics Inc and Bluebird Bio Inc to have its specialty pharmaceutical business exclusively distribute their new hemophilia therapies when they are expected to become available in 2019 and 2020, Chief Medical Officer Steve Miller told Reuters in an interview.

  • Options Traders Expect Huge Moves in Express Scripts (ESRX) Stock
    Zacks2 months ago

    Options Traders Expect Huge Moves in Express Scripts (ESRX) Stock

    Express Scripts (ESRX) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Glenview Scores Win over Carl Icahn as ISS Supports Cigna’s Deal Plan
    Bloomberg2 months ago

    Glenview Scores Win over Carl Icahn as ISS Supports Cigna’s Deal Plan

    The recommendation is at odds with billionaire investor Carl Icahn’s efforts to drum up investor opposition to the takeover of the pharmacy benefit manager ahead of an Aug. 24 shareholder vote. Institutional Shareholder Services Inc. urged investors to support the deal. “For investors with exposure to both sides of this equation, the value proposition of a combination is straightforward: the potential benefits of the combination outweigh the risks, especially given that these risks are, to some degree, unavoidable,” ISS said in the report.